The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | An insight into future treatments for MM and their complications
Nikhil Munshi, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, USA, provides us with an insight into the potential treatments for multiple myeloma (MM) and their justifications. Potential targets detailed by Dr. Munshi include designing antibodies against anti-IL-17 and anti-PD1/PDL1, which could then be combined with immunomodulators such as lenalidomide to augment their therapeutic response. Another potential therapy is the combination of vaccines with lenalidomide, which would hypothetically prolong the drug’s therapeutic effect. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
